Tyra Biosciences (TYRA) Operating Leases (2021 - 2026)

Tyra Biosciences (TYRA) has 6 years of Operating Leases data on file, last reported at $5.2 million in Q1 2026.

• Quarterly Operating Leases fell 8.55% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 8.55% YoY) and the FY2025 annual result came in at $5.3 million, down 8.12% from the prior year.
• Operating Leases retreated to $5.2 million in Q1 2026, from $5.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.2 million in Q4 2023 to a low of $2.4 million in Q1 2023.
• A 5-year average of $5.0 million and a median of $5.6 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases soared 153.01% — and 2023, when it tumbled 55.56%.
• Tracing TYRA's Operating Leases over 5 years: stood at $2.5 million in 2022, then surged by 150.44% to $6.2 million in 2023, then dropped by 6.53% to $5.8 million in 2024, then fell by 8.12% to $5.3 million in 2025, then fell by 2.42% to $5.2 million in 2026.
• The last three Operating Leases figures came in at $5.2 million (Q1 2026), $5.3 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.